BC3402
As of the edition of 20 October 2026, BC3402 is a drug known only by a code name: stopped in 2026; acts on HAVCR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Code name only
- Registered trials
- 4, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HAVCR2 | Hepatitis A virus cellular receptor 2 | Q8TDQ0 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 0 | 0 | 0 |
| Phase 2 | 2 | 0 | 0 | 1 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Biocity Biopharmaceutics | Lead sponsor of trials | 2023 to now |